



Theradiag signs a fourth microRNA partnership agreement with CNRS

The company will gain access to a full diagnostics and theranostics portfolio in Rheumatoid Arthritis

Croissy-Beaubourg and Montpellier, April 8, 2014 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and *in vitro* diagnostics, has signed a fourth research partnership agreement in microRNAs with the French National Center for Scientific Research (CNRS) / the Institute of Molecular Genetics of Montpellier (IGMM) and the University of Montpellier (UM1 and 2) for the development of diagnostics and theranostics tools in Rheumatoid Arthritis (RA).

The purpose of this new development program is to identify, on a cohort of 100 patients, microRNA signatures which would improve diagnosis of RA, allow for analysis of disease-activity and severity parameters, and most importantly, provide prognosis information regarding response to treatment. These findings could be the subject of a joint patent application by Theradiag and CNRS.

“There are currently very few tools enabling physicians to adapt RA therapies to each patient and choose one treatment over another. Identifying prognosis factors for response to treatment would bring a huge benefit to RA patients,” comments Professor Gérard Tobelem, Chairman of Theradiag.

With this new development, Theradiag significantly strengthens its positioning in the auto-immune diseases segment, and should offer, in the near future, a complete diagnostics and theranostics portfolio in RA including:

- Disease diagnosis (available FIDIS™ product range and microRNA test under development);
- Disease monitoring (microRNA test under development);
- Monitoring of biotherapies for the disease (available LISA-TRACKER portfolio);
- Identification of treatment response prognosis factors (microRNA test under development).

“Our development and partnering strategy is clear: we want Theradiag to remain a ground-breaking company leading the field of theranostics for auto-immune diseases, alongside our other microRNA developments in AIDS and cancer. Our goal for 2014 is to strengthen the initiatives launched in 2013 and to build new partnerships which will help us increase our theranostics portfolio and accelerate the sales of our products,” concludes Michel Finance, CEO of Theradiag.

About Theradiag

Backed by its expertise in the distribution, development and manufacturing of *in vitro* diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficiency and the prevention of drug resistance. Theradiag markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is also developing new diagnostics biomarkers thanks to its microRNA platform, in order to diagnose and monitor HIV/AIDS and rectal cancer. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 55 employees.

For more information about Theradiag, please visit our website: www.theradiag.com



ALTER
LISTED
NYSE
ALTERNEXT

Theradiag

Relations investisseurs

Nathalie Trepo

Tél: 01 64 62 10 12

ntrepo@theradiag.com

NewCap.

Communication financière
et Relations Investisseurs

Valentine Brouchet /

Pierre Laurent

Tél. : 01 44 71 94 94

theradiag@newcap.fr

Alize RP

Relations Presse

Caroline Carmagnol

caroline@alizerp.com

Tél. : 06 64 18 99 59